• Source : Press Release
  • Date : 2020-12-10
  • Event type : Marketed
  • Companies : UCB Pharma S.A.

'Reimbursement for Amgen's Evenity Will Benefit High-Risk Osteoporosis Patients'

Amgen Korea will create the best environment to treat osteoporosis patients who are at a very high risk of fracture with Evenity, which recently began to receive insurance benefits, the company said Thursday.

Professor Kim Duk-yoon of the Department of Endocrinology and Metabolism at KyungHee University Medical Center explains the benefits of Amgen Korea's osteoporosis treatment, Evenity, during an online conference held by Amgen on Thursday.

"The annual treatment cost for osteoporotic fracture exceeds that of breast cancer, myocardial infarction, and stroke," Professor Kim Duk-yoon of the Department of Endocrinology and Metabolism at KyungHee University Medical Center said during the company's media event.

One in three women over 50 will experience osteoporosis-related fractures during the remainder of their lives. With the aging population in Asia, the incidence of vulnerable fractures increases significantly in the region, Kim added.

Despite the fracture risk, a recent study showed that postmenopausal women with osteoporotic fractures do not receive treatment, Kim added.

The professor pointed out that while bone formation drugs should be used in women at very high risk for fractures, less than 1 percent of such patients are treated.

"If patients experience an osteoporotic fracture, they should be diagnosed with osteoporosis with or without a bone mineral density test," he said. "After diagnosis, it is important to lower the risk of fracture through strong drug treatment, such as Evenity, from the early stage of treatment for the patients who are at ultra-high risk of suffering from an osteoporotic fracture."

The reimbursement of Evenity will enable more sophisticated and effective osteoporosis treatment according to fracture risk while also allowing customized treatment for the ultra-high-risk fracture group in the clinical field.

Professor Kim explained that the treatment paradigm for treating osteoporosis patients who are at ultra-high-risk of fracture is already changing in advanced countries.

"The recently published guidelines of the American Society of Clinical Endocrinology and American College of Endocrinology have newly defined very-high-risk osteoporosis group, which requires strong drug therapy from the initial treatment," Kim said. "With the addition of the new definition, both associations recommend physicians to actively reduce the risk of fractures by using Evenity regimen as the primary treatment option."

During the conference, Kim Sang-yoon, head of Amgen Korea General Medicine Division, also explained the implications of Evenity receiving insurance benefits.

"Evenity receiving reimbursement benefits will be an opportunity to improve access to treatment for ultra-high-risk groups for osteoporosis fractures," Kim said.

Amgen Korea is striving to establish the drug as a standard treatment for ultra-high-risk fractures while working with local medical staff to develop long-term osteoporosis treatment strategies, ranging from Evenity effective on strong initial treatment to Prolia suitable for continuous treatment, she added.